Autoimmune and inflammatory diseases affect millions of Americans, and many patients struggle with treatments that provide incomplete relief or carry significant side effects. Researchers are investigating whether adipose-derived mesenchymal stromal cells (ADSCs) could play a role in addressing these complex conditions. This guide walks through the current clinical evidence, the regulatory lessons learned from the first approved adipose-derived cell product, and what the evolving research landscape means for patients considering adipose tissue banking.
TLDR Adipose-derived stem cells are among the most actively studied cell types for autoimmune and inflammatory conditions, with Crohn’s disease alone accounting for 85 clinical trials worldwide. The only adipose-derived MSC product to reach market approval (Alofisel, for Crohn’s fistulas in Europe) was later withdrawn when a larger confirmatory trial failed. No ADSC product is FDA-approved for any autoimmune disease in the United States. Research continues actively across multiple conditions, but all such therapies remain investigational and unapproved. Save My Fat banks intact adipose tissue under 361 HCT/P regulations for potential future use in FDA-regulated pathways. Banking does not guarantee eligibility for any clinical trial, access to any therapy, or clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including autoimmune conditions. No adipose-derived stem cell product currently has FDA approval for the treatment of any autoimmune or inflammatory disease in the United States. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Autoimmune diseases affect an estimated 24 million Americans, according to the National Institutes of Health. Conditions like Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis occur when the immune system mistakenly attacks the body’s own tissues. For many patients, existing treatments provide incomplete relief or come with significant side effects.
Because adipose-derived mesenchymal stromal cells demonstrate immunomodulatory properties in laboratory and early clinical research, they have become one of the most actively investigated cell types for autoimmune and inflammatory conditions worldwide. Understanding the difference between legitimate clinical research and unregulated clinic marketing is critical for patient safety. This guide walks through the most important clinical evidence, explains the Alofisel regulatory case study in detail, and clarifies how adipose tissue banking fits into this research landscape.
Why Autoimmune Diseases Are a Focus of ADSC Research
Autoimmune diseases arise from a breakdown in immune tolerance, where the body’s defense system attacks its own healthy tissues. The immunomodulatory properties of mesenchymal stromal cells, including those derived from adipose tissue, have made them a subject of sustained scientific interest for these conditions.
In laboratory research, ADSCs have been shown to interact with multiple components of the immune system. Published studies report that ADSCs can suppress T-cell proliferation, inhibit dendritic cell maturation, shift macrophage polarization from inflammatory (M1) to anti-inflammatory (M2) phenotypes, and promote the development of regulatory T cells. These effects appear to be mediated through the secretion of soluble factors, including indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE-2), transforming growth factor-beta (TGF-B), and interleukin-10 (IL-10). (PMC11817852)
A 2025 global analysis of clinical trial data from 2006 to 2025, published in Frontiers in Immunology, identified 244 interventional stem cell therapy trials across autoimmune diseases. Crohn’s disease led with 85 trials (34.8%), followed by systemic lupus erythematosus with 36 trials (14.8%) and scleroderma with 32 trials (13.1%). The United States and China led in trial numbers, and academic institutions funded 49.2% of all trials. (PMC12328461)
Important: Laboratory findings do not automatically translate to safe or effective therapies in humans. The path from laboratory observation to proven clinical treatment requires years of rigorous testing through properly designed trials.
Crohn’s Disease Perianal Fistulas: The Most Advanced ADSC Research
Complex perianal fistulas are one of the most debilitating complications of Crohn’s disease, and they represent the autoimmune condition where adipose-derived stem cell research has advanced the furthest. This area also provides an important case study in how the regulatory process works and why it matters.
The Alofisel (Darvadstrocel) Story
Darvadstrocel (brand name Alofisel) was a suspension of allogeneic (donor-derived) expanded adipose-derived mesenchymal stem cells developed by TiGenix (later acquired by Takeda) for complex perianal fistulas in adults with Crohn’s disease.
ADMIRE-CD Phase 3 Trial: The registrational Phase 3 trial randomized 212 patients to receive either darvadstrocel (120 million cells injected around the fistula tract) or placebo. At 24 weeks, the darvadstrocel group showed a combined remission rate of 56.3% compared to 38.6% for placebo, a statistically significant difference of 15.8 percentage points. (EMA)
EMA Approval (2018): Based on this data, the European Medicines Agency granted marketing authorization in March 2018. Japan’s Ministry of Health, Labour and Welfare approved Alofisel in September 2021. (EMA)
ADMIRE-CD II and Withdrawal: As a post-authorization requirement, Takeda conducted ADMIRE-CD II, a larger randomized placebo-controlled study of 568 patients. In October 2023, Takeda announced that this confirmatory trial did not meet its primary endpoint of combined remission at 24 weeks. No statistical differences were observed in any secondary endpoints. The safety profile remained consistent with prior studies, with no new safety signals. (Takeda)
In December 2024, Takeda voluntarily withdrew the EU marketing authorization for Alofisel. Takeda stated it was also engaging health authorities in other countries where Alofisel remained approved. (EMA) (Takeda)
Why This Story Matters for Patients
The Alofisel arc demonstrates several critical realities about regenerative medicine. Regulatory approval is not permanent; products must continue to demonstrate clinical benefit through confirmatory studies. Even after an adipose-derived stem cell product achieved the highest level of regulatory approval in a major market, subsequent data led to its removal. The regulatory system protects patients by requiring confirmatory evidence, and science is iterative, meaning a single positive trial does not prove a product “works.” Replication in larger, independent studies is essential.
Ongoing Crohn’s Fistula Research
Research into adipose-derived cells for Crohn’s fistulas continues despite the Alofisel withdrawal.
AlloFIST Trial (NCT06636032): A Phase I/II dose-escalation study at Toulouse University Hospital is evaluating CellReady, an allogeneic adipose-derived MSC product, injected directly into fistula walls at two dose levels (50 million and 100 million cells) for complex perianal fistulas in Crohn’s disease. The trial is currently recruiting.(ClinicalTrials.gov)
Real-World Data: A 2025 retrospective study from Spain’s Galician Health Service reported that among 26 patients treated with darvadstrocel before its withdrawal, combined remission was achieved in 69.2% at 6 months and 57.7% at 12 months, with no treatment-related adverse events. The authors noted these remission rates were consistent with or slightly higher than the original ADMIRE-CD trial results, though the observational design and small sample size warrant cautious interpretation. (PMC12513338)
Rheumatoid Arthritis: Phase I/IIa Data With Adipose-Derived MSCs
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that affects approximately 1.3 million Americans. Several clinical trials have investigated adipose-derived MSCs for RA patients who have not responded adequately to conventional treatments.
Published Clinical Trial Data
Phase I/IIa Trial (NCT03691909): A published, open-label, non-randomized study enrolled 15 eligible RA patients aged 18 to 65 years who received a single intravenous dose of 200 million autologous adipose-derived MSCs. Patients were followed at weeks 4, 12, 26, and 52. ACR66/68 scores for both swollen and tender joint counts showed statistically significant improvements with large effect sizes at week 52 compared to baseline. No acute or long-term serious adverse events were reported. (PMC8896321)
The authors concluded the data support further investigation in larger, controlled trials. However, important limitations include the small sample size (15 patients), open-label design (no placebo comparison), and sponsorship by the cell therapy company. (PMC8896321)
Multi-condition MSC Trial (NCT06888973): A double-blind, randomized, placebo-controlled trial is evaluating mesenchymal stem cell therapy across multiple autoimmune diseases including RA, systemic lupus erythematosus, systemic sclerosis, ankylosing spondylitis, and dermatomyositis. The study uses DAS28-ESR as its primary outcome for the RA cohort, with follow-up at 12, 24, and 48 weeks. (ClinicalTrials.gov)
2025 Meta-Analysis
A February 2025 systematic review and meta-analysis published in Stem Cell Research and Therapy analyzed 42 randomized controlled trials encompassing 2,183 participants across multiple autoimmune and rheumatic diseases. The analysis found that MSC transplantation (from various sources including adipose, bone marrow, and umbilical cord) showed statistically significant improvements in pain scores for osteoarthritis and disease activity indices for inflammatory bowel disease and systemic lupus erythematosus. Importantly, MSC transplantation did not increase the incidence of adverse events across any of the conditions studied. (PMC11817852)
The review authors emphasized that while these results are encouraging, the heterogeneity of trial designs, MSC sources, dosing protocols, and outcome measures makes it difficult to draw definitive conclusions.(PMC11817852)
Regulatory note: No adipose-derived MSC product is approved by the FDA for rheumatoid arthritis. All such therapies remain investigational. Clinics marketing stem cell injections as treatments for RA are promoting unapproved products.
Systemic Lupus Erythematosus (SLE): Early-Phase Investigations
Systemic lupus erythematosus is a complex autoimmune disease that can affect multiple organ systems. MSC therapy, including adipose-derived cells, has been investigated primarily in treatment-refractory cases. The 2025 meta-analysis of 42 RCTs found that MSC transplantation significantly improved SLEDAI (disease activity) scores compared to controls, with a standardized mean difference of negative 2.32 (P = 0.0003). (PMC11817852)
However, important limitations apply. Most SLE studies to date were open-label or single-arm, lacking placebo control groups. Many studies used bone marrow or umbilical cord-derived MSCs rather than specifically adipose-derived cells. Sample sizes were generally small, and long-term follow-up data remain limited.
The global clinical trials analysis identified 36 stem cell therapy trials for SLE, making it the second most-studied autoimmune indication after Crohn’s disease. (PMC12328461)
Multiple Sclerosis, GVHD, and Other Autoimmune Conditions
Multiple Sclerosis (MS)
Hope Biosciences Phase 2 Trial (NCT06800404): An open-label, single-center Phase 2 study is evaluating multiple doses of autologous adipose-derived mesenchymal stem cells for patients with relapsing-remitting multiple sclerosis. This trial follows earlier Phase 1 safety data from the same research group. (ClinicalTrials.gov)
Earlier Phase I/II studies of MSCs from various sources in MS patients reported no serious adverse events and observed increases in regulatory T cell proportions following infusion. However, small sample sizes and open-label designs limit interpretation of any efficacy signals observed.
Graft-Versus-Host Disease (GVHD)
GVHD is a life-threatening complication of allogeneic hematopoietic stem cell transplantation. Approximately 50% of acute GVHD cases are resistant to steroid treatment, and two-year mortality in steroid-resistant patients exceeds 80%. While the only FDA-approved MSC product for GVHD (Ryoncil/remestemcel-L) uses bone marrow-derived cells, the immunomodulatory mechanisms are shared across MSC sources, including adipose tissue. The GVHD research establishes proof-of-concept that MSC-based immunomodulation can achieve regulatory-grade evidence in autoimmune and inflammatory contexts.(FDA)
Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)
NCT06574581: A Phase I/IIa, open-label clinical trial is evaluating allogeneic adipose tissue-derived MSCs for refractory or rapidly progressive interstitial lung disease in 10 patients with connective tissue disease. The study uses a dose-escalation design, starting with a single infusion of 1 million cells per kilogram. (ClinicalTrials.gov)
Understanding the Evidence Hierarchy
When reading about stem cell research for autoimmune diseases, patients should understand the current state of evidence:
| Evidence Level | Description | Current ADSC Autoimmune Status |
|---|---|---|
| Strong Evidence | Large, multi-center, randomized, placebo-controlled Phase 3 trials with confirmed replication | Alofisel achieved this for Crohn’s fistulas (ADMIRE-CD), but the confirmatory ADMIRE-CD II trial failed and the product was withdrawn |
| Moderate Evidence | Phase 2 randomized controlled trials showing statistically significant benefit | Some Phase 2 data exist for RA and OA but are generally small, single-center, or open-label |
| Preliminary Evidence | Phase 1 safety studies, case series, small open-label trials | This is where most ADSC autoimmune research currently stands |
| Preclinical Evidence | Laboratory studies and animal models | Extensive preclinical data support immunomodulatory mechanisms, but translation to humans is not guaranteed |
The 2025 global clinical trials analysis found that 83.6% of stem cell therapy trials for autoimmune diseases remain in Phase I-II. This means the vast majority of research is still in early stages focused on safety assessment and preliminary efficacy signals, not on confirming effectiveness through the large controlled trials required for regulatory approval. (PMC12328461)
The Safety Profile in Autoimmune Applications
Across published trials of ADSCs and other MSCs in autoimmune conditions, the safety profile has been generally favorable. The 2025 meta-analysis of 42 RCTs found that MSC transplantation did not significantly increase the incidence of adverse events compared to control groups across osteoarthritis, SLE, inflammatory bowel disease, or multiple sclerosis. (PMC11817852)
The most common adverse events include transient fever, mild injection site reactions, and headache. The Alofisel safety database across multiple trials and real-world use showed no new safety signals even when the confirmatory efficacy trial failed. (EMA)
Important limitations: Follow-up periods in most trials remain relatively short, typically 6 to 24 months. Long-term safety data, particularly regarding tumor surveillance in immunocompromised autoimmune patients, are still limited. Patients with autoimmune diseases receiving immunosuppressive medications may have different risk profiles than those studied in other ADSC contexts. These gaps must be addressed in future research before definitive safety conclusions can be drawn.
What This Means for Adipose Tissue Banking
The autoimmune disease research landscape illustrates both the promise and the complexity of adipose-derived cell science. Researchers are actively investigating ADSCs across a range of immune-mediated conditions, from Crohn’s disease to rheumatoid arthritis to multiple sclerosis.
The Alofisel story provides a balanced view. It demonstrated that an adipose-derived MSC product could navigate the full regulatory approval process in a major market, receive marketing authorization based on Phase 3 data, and be used in real-world clinical practice. At the same time, the failure of the confirmatory trial and subsequent market withdrawal shows that the path from promising science to established treatment is neither linear nor guaranteed.
Save My Fat helps individuals preserve their own adipose tissue through validated cryopreservation protocols for potential future opportunities. The ongoing and expanding clinical trial landscape for ADSCs in autoimmune diseases represents one area of active scientific investigation where adipose tissue may play a role in the future, should products successfully complete the rigorous FDA approval process.
Banking adipose tissue today does not guarantee:
- Eligibility for any autoimmune disease clinical trial
- Access to any investigational immunomodulatory product
- That banked tissue will be compatible with future research protocols
- Clinical benefit from any future therapy
Any future use depends on the regulatory status of products or procedures at that time, the patient’s clinical situation, physician guidance, and availability of FDA-regulated pathways including clinical trials, Expanded Access programs, or future approved therapies.
Frequently Asked Questions
Q: Are adipose-derived stem cells FDA-approved for any autoimmune disease?
A: No. No adipose-derived stem cell product has FDA approval for any autoimmune disease in the United States. The only FDA-approved MSC product (Ryoncil) uses bone marrow-derived cells for pediatric steroid-refractory acute GVHD. All adipose-derived therapies for autoimmune conditions remain investigational and unapproved. Any clinic claiming otherwise is misrepresenting the product’s regulatory status.(FDA)
Q: What happened with Alofisel for Crohn’s disease?
A: Alofisel (darvadstrocel) was an allogeneic adipose-derived MSC product that received EMA approval in 2018 for complex perianal fistulas in Crohn’s disease based on Phase 3 trial data. However, the larger confirmatory trial (ADMIRE-CD II, 568 patients) did not meet its primary endpoint. Takeda voluntarily withdrew the EU marketing authorization in December 2024. This illustrates why confirmatory studies are required and why regulatory systems include post-approval oversight.
Q: Why are researchers interested in adipose-derived stem cells for autoimmune conditions?
A: ADSCs demonstrate immunomodulatory properties in laboratory research, including the ability to suppress T-cell activation, shift macrophage polarization, and promote regulatory T cell development. These properties are potentially relevant to conditions where the immune system attacks the body’s own tissues. However, laboratory properties do not automatically translate to safe or effective therapies, and extensive clinical testing is required.
Q: How many clinical trials are studying stem cells for autoimmune diseases?
A: A 2025 global analysis identified 244 interventional trials studying stem cell therapies across autoimmune diseases from 2006 to 2025. Crohn’s disease (85 trials), systemic lupus erythematosus (36 trials), and scleroderma (32 trials) were the most studied conditions. The majority (83.6%) remain in early phases (Phase I-II).
Q: Can I use banked adipose tissue for autoimmune disease treatment?
A: Banking adipose tissue is a preservation service, not a treatment for any condition. Whether banked tissue could ever be used in a clinical trial or approved therapy depends entirely on future scientific developments, FDA regulatory decisions, individual trial protocols, and your clinical situation. There is no current pathway to use banked adipose tissue as a treatment for autoimmune disease outside of a properly regulated clinical trial or future approved therapy.
Q: Does the Alofisel withdrawal mean adipose stem cell research for autoimmune diseases has failed?
A: No. The Alofisel withdrawal reflects the outcome of one specific confirmatory trial for one specific product in one specific condition. Research into adipose-derived cells for autoimmune diseases continues actively, with new trials such as AlloFIST (NCT06636032) investigating next-generation approaches. Science is iterative, and individual trial outcomes do not determine the trajectory of an entire field. At the same time, the withdrawal is a reminder that promising early results do not guarantee proven, lasting treatments.
Q: Are there differences between the MSC sources used in autoimmune disease trials?
A: Yes. Clinical trials for autoimmune diseases have used MSCs from adipose tissue, bone marrow, and umbilical cord sources. The 2025 meta-analysis noted that while all sources showed potential immunomodulatory effects, the specific cell source, dosing protocol, and administration route may influence outcomes. Standardization across these variables remains an ongoing challenge in the field.
Q: What should I watch for when evaluating clinics offering stem cell treatments for autoimmune diseases?
A: Be cautious of any clinic that claims stem cell treatments are FDA-approved for autoimmune diseases, guarantees specific outcomes, charges large fees to “participate” in a clinical trial, does not have ClinicalTrials.gov registration, or markets treatments directly to consumers with cure promises. Legitimate clinical trials are registered on ClinicalTrials.gov, have IRB oversight, and do not typically charge patients for the investigational product. The FDA consumer alert on regenerative medicine provides guidance on identifying unproven therapies.
Key Takeaways
- No adipose-derived stem cell product is FDA-approved for any autoimmune or inflammatory disease in the United States. All such therapies remain investigational and unapproved.
- Crohn’s disease perianal fistulas represent the most advanced area of ADSC autoimmune research. Alofisel (darvadstrocel) achieved EMA approval in 2018 but was withdrawn in December 2024 after the larger confirmatory trial (ADMIRE-CD II) failed to meet its primary endpoint.
- A 2025 global analysis identified 244 interventional clinical trials studying stem cell therapies for autoimmune diseases, with 83.6% remaining in early Phase I-II stages.
- A 2025 meta-analysis of 42 RCTs (2,183 participants) found that MSC transplantation showed statistically significant improvements in several autoimmune disease activity measures and did not increase adverse event rates compared to controls.
- The Alofisel story demonstrates that the regulatory system works as designed. Post-authorization monitoring protects patients by requiring products to continue demonstrating benefit. Promising early results do not guarantee proven treatments.
- Save My Fat banks intact adipose tissue under 361 HCT/P regulations for potential future use. Banking does not guarantee eligibility for any trial, access to any therapy, or clinical benefit from any future product.
Ready to Learn More About Adipose Tissue Banking?
You now understand the current state of clinical research investigating adipose-derived stem cells for autoimmune and inflammatory diseases. Researchers around the world are conducting legitimate, FDA-regulated clinical trials to determine whether these cells may eventually offer new options for patients. These studies require years of rigorous scientific evaluation before any product can receive marketing approval.
Save My Fat helps individuals preserve adipose tissue through validated cryopreservation protocols for potential future use in FDA-regulated pathways. We focus on education, honesty about limitations, and positioning patients for legitimate opportunities, not making disease-cure promises.
Here is what we offer:
- Comprehensive consultation to discuss your goals and answer questions
- Transparent information about the banking process, costs, and realistic expectations
- Validated cryopreservation protocols supported by peer-reviewed research
- Long-term storage in controlled facilities with proper documentation
- Educational resources about FDA pathways, clinical trials, and patient safety
- Honest communication about what tissue banking is, and what it is not
Ready to learn more?
Contact Save My Fat today.
Schedule a consultation to discuss whether adipose tissue banking aligns with your health planning goals.
- What Is Adipose Tissue Banking? A Complete Guide
- How Stem Cell Banking Works
- Pricing
- For Providers
- Family Eligibility
Save My Fat Adipose Tissue Banking for Future Regenerative Medicine Opportunities
Last Updated: March 23, 2026.
